ArticleHaematologica2016
Acute myeloid leukemia patients' clinical response to idasanutlin (RG7388) is associated with pre-treatment MDM2 protein expression in leukemic blasts.
Open access · goldAbstract readClinical Trial, Phase ILetter
In one paragraph
Article in Haematologica, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed
8.9field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 90 citations in OpenAlex.
- Delivery of ATSP-7041 by Minimally Invasive Nasal Depot (MIND) to Target Diffuse Intrinsic Pontine Glioma.Molecular cancer therapeutics · 2026Article
- Targeting "undruggable" cancer proteins: pharmacological challenges and emerging strategies.Translational cancer research · 2026Review
- Ubiquitin System-Driven Proteostasis in DNA Damage Response.International journal of molecular sciences · 2026Review
- Article
- From Crypts to Cancer: A Holistic Perspective on Colorectal Carcinogenesis and Therapeutic Strategies.International journal of molecular sciences · 2024Review
- MDM2: current research status and prospects of tumor treatment.Cancer cell international · 2024Review
- p53 biology and reactivation for improved therapy in MDS and AML.Biomarker research · 2024Review
- Enhanced Expression of Glycolytic Enzymes and Succinate Dehydrogenase Complex Flavoprotein Subunit A by Mesothelin Promotes Glycolysis and Mitochondrial Respiration in Myeloblasts of Acute Myeloid Leukemia.International journal of molecular sciences · 2024Article
- Recent advances in targeting the "undruggable" proteins: from drug discovery to clinical trials.Signal transduction and targeted therapy · 2023Review
- p53 Regulates the Extent of Fibroblast Proliferation and Fibrosis in Left Ventricle Pressure Overload.Circulation research · 2023Article
- BI-907828, a novel potent MDM2 inhibitor, inhibits glioblastoma brain tumor stem cells in vitro and prolongs survival in orthotopic xenograft mouse models.Neuro-oncology · 2023Article
- An MDM2 degrader for treatment of acute leukemias.Leukemia · 2023Article
- miR-16-5p enhances sensitivity to RG7388 through targetingCancer drug resistance (Alhambra, Calif.) · 2023Article
- MDM2 antagonist improves therapeutic activity of azacitidine in myelodysplastic syndromes and chronic myelomonocytic leukemia.Leukemia & lymphoma · 2022Article
- Genome-wide CRISPR/Cas9 screening for therapeutic targets in NSCLC carrying wild-type TP53 and receptor tyrosine kinase genes.Clinical and translational medicine · 2022Article
- GATA3 and MDM2 are synthetic lethal in estrogen receptor-positive breast cancers.Communications biology · 2022Article
- Early-Stage Lung Adenocarcinoma MDM2 Genomic Amplification Predicts Clinical Outcome and Response to Targeted Therapy.Cancers · 2022Article
- Green tea-derived theabrownin induces cellular senescence and apoptosis of hepatocellular carcinoma through p53 signaling activation and bypassed JNK signaling suppression.Cancer cell international · 2022Article
- Combined MEK/MDM2 inhibition demonstrates antitumor efficacy in TP53 wild-type thyroid and colorectal cancers with MAPK alterations.Scientific reports · 2022Article
- Resistance mechanisms to inhibitors of p53-MDM2 interactions in cancer therapy: can we overcome them?Cellular & molecular biology letters · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 13 institutions in 8 countries.
Bernhard ReisRoche Innovation Center Basel, Roche Pharma Research and Early Development, Switzerland.
Lori JukofskyRoche Innovation Center New York, Roche Pharma Research and Early Development, NY, USA.
Gong ChenRoche Innovation Center New York, Roche Pharma Research and Early Development, NY, USA.
Giovanni MartinelliSeragnoli Institute of Hematology, Bologna University School of Medicine, Italy.
Hua ZhongRoche Innovation Center New York, Roche Pharma Research and Early Development, NY, USA.
W Venus SoRoche Innovation Center New York, Roche Pharma Research and Early Development, NY, USA.
Michael J DickinsonDepartment of Haematology, Peter MacCallum Cancer Center, Melbourne, VIC, Australia.
Mark DrummondBeatson West of Scotland Cancer Center, Gartnavel General Hospital, Glasgow, United Kingdom.
Sarit AssoulineDivision of Hematology, Jewish General Hospital, McGill University, Montreal, QC, Canada.
Maneja HashemyanRoche Innovation Center New York, Roche Pharma Research and Early Development, NY, USA.
Michel TheronRoche Innovation Center Basel, Roche Pharma Research and Early Development, Switzerland.
Steven BlotnerRoche Innovation Center New York, Roche Pharma Research and Early Development, NY, USA.
Je-Hwan LeeDepartment of Hematology, Asian Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Margaret KasnerKimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA.
Sung-Soo YoonDepartment of Internal Medicine, Seoul National University School of Medicine, Seoul, South Korea.
Ruediger RuegerRoche Innovation Center Penzberg, Roche Pharma Research and Early Development, Germany.
Karen SeiterNew York Medical College, Valhalla, NY, USA.
Steven A MiddletonRoche Innovation Center New York, Roche Pharma Research and Early Development, NY, USA.
Kevin R KellyUniversity of Southern California, Norris Comprehensive Cancer Center, Los Angeles, CA, USA.
Norbert VeyHematology, Institut Paoli Calmettes, Marseilles, France.
Karen YeePrincess Margaret Hospital, Toronto, ON, Canada.
Gwen NicholsRoche Innovation Center New York, Roche Pharma Research and Early Development, NY, USA.
Lin-Chi ChenRoche Innovation Center New York, Roche Pharma Research and Early Development, NY, USA.
William E PierceallRoche Innovation Center New York, Roche Pharma Research and Early Development, NY, USA william.pierceall@roche.com.
La Roche College · USRoche (Switzerland) · CHBeatson West of Scotland Cancer Centre · GBInstitut Pprime · FRJewish General Hospital · CANew York Medical College · USPeter MacCallum Cancer Centre · AUPrincess Margaret Cancer Centre · CARoche Pharma AG (Germany) · DESeoul National University · KRThomas Jefferson University · USUniversity of Southern California · USUniversity of Ulsan · KR
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Blast CrisisLeukemia, Myeloid, AcuteFemaleGene Expression Regulation, LeukemicHumansMalepara-AminobenzoatesProto-Oncogene Proteins c-mdm2PyrrolidinesMDM2 protein, humanpara-AminobenzoatesProto-Oncogene Proteins c-mdm2PyrrolidinesRG7388AMLcomplementary diagnosticsflow cytometryidasanutlinMDM2 antagonism
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.